Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
As of September 30, 2025, cash and cash equivalents and short-term investments were approximately $86.1 million. Shattuck's...
-SEC Filing
Wedbush analyst David Nierengarten initiates coverage on Shattuck Labs (NASDAQ:STTK) with a Outperform rating and announces ...
– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Diseas...
Leerink Partners analyst Faisal Khurshid maintains Shattuck Labs (NASDAQ:STTK) with a Outperform and lowers the price target...
Needham analyst James Ricchiuti reiterates Shattuck Labs (NASDAQ:STTK) from Hold to Hold.
